Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1998-9-15
pubmed:abstractText
The prognostic significance of immunohistochemical markers for cell proliferation [MIB-1, proliferating cell nuclear antigen (PCNA)] and hormone receptor analysis [oestrogen receptor (ER), progesterone receptor (PR)] was tested by means of immunohistometry in a series of 103 breast cancer patients in comparison with the lymph node status N, the tumour size T, histomorphological grading, and the biochemical ER and PR status. Immunohistochemical reactions were performed on 2 microns sections from paraffin-embedded tissue, using an indirect peroxidase method. The proportion of immunostained tumour cell nuclei was determined using a TV-image analysis system. Measurements were performed using a 20 x objective on 40 viewing fields (1.94 mm2, MIB-1 and PCNA) or 20 viewing fields (0.97 mm2, ER and PR). The mean immunopositivity of all viewing fields and the value of the most immunopositive viewing field (MIB-1max, PCNAmax, PRmax, ERmax) were calculated. The mean values and the maximal values were highly correlated (r = 0.903, P < 0.001). After 1:2:1 quantilization, 84.2 per cent of the 412 single measurements revealed mean and maximal values in the same category (P < 0.0001). For each of the four immunohistochemical markers, the prognostic significance of the maximal values was higher than that of the mean values. The highest prognostic significance was found for MIC-1max (P = 0.0002), followed by PRmax (P = 0.0046), ERmax (P = 0.0154), and PCNAmax (P = 0.0161). From the results of a Cox model, a 'prognostic index (PI)' was developed, ranging from -1 to 8: PI = 2 x N + T + MIB-1max-PRmax. The four groups of patients with PI values of < 2, 2-3, 4-5, and > 5 revealed significantly different 7.5-year survival probabilities (P < 0.0001). The simplicity of the PI makes it a clinically useful, routinely applicable, and understandable parameter in the surgical pathology of breast carcinoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0022-3417
pubmed:author
pubmed:issnType
Print
pubmed:volume
185
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
25-31
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:9713356-Adult, pubmed-meshheading:9713356-Aged, pubmed-meshheading:9713356-Analysis of Variance, pubmed-meshheading:9713356-Breast Neoplasms, pubmed-meshheading:9713356-Female, pubmed-meshheading:9713356-Follow-Up Studies, pubmed-meshheading:9713356-Humans, pubmed-meshheading:9713356-Image Processing, Computer-Assisted, pubmed-meshheading:9713356-Immunoenzyme Techniques, pubmed-meshheading:9713356-Ki-67 Antigen, pubmed-meshheading:9713356-Middle Aged, pubmed-meshheading:9713356-Observer Variation, pubmed-meshheading:9713356-Prognosis, pubmed-meshheading:9713356-Proliferating Cell Nuclear Antigen, pubmed-meshheading:9713356-Prospective Studies, pubmed-meshheading:9713356-Receptors, Estrogen, pubmed-meshheading:9713356-Receptors, Progesterone, pubmed-meshheading:9713356-Survival Rate, pubmed-meshheading:9713356-Tumor Markers, Biological
pubmed:year
1998
pubmed:articleTitle
Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumour focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER, and PR.
pubmed:affiliation
Institute of Pathology, Technical University of Aachen, Germany.
pubmed:publicationType
Journal Article